Injectable formulations for treating cancer

Patent metadata

Field	Value
Publication number	US-2021251887-A1
Application number	US-202017130936-A
Country	US
Kind code	A1
Filing date	Dec 22, 2020
Priority date	Sep 17, 2014
Publication date	Aug 19, 2021
Grant date	—

Abstract

The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

First claim

1 . A formulation comprising a compound of Formula (I):

or an N-oxide, a hydrate, or salt thereof, a solubilizer, and a pH adjustment reagent, wherein the formulation comprises about 1-10% (w/v) compound of Formula (I) and about 4-40% (w/v) solubilizer.

2 . The formulation of claim 1 , comprising about 10% (w/v) compound of Formula (I).

3 . The formulation of claim 1 , comprising about 40% (w/v) solubilizer.

4 . The formulation of claim 1 , wherein the solubilizer is a cyclodextrin.

5 . The formulation of claim 4 , wherein the cyclodextrin is Hydroxypropyl Betadex.

6 . The formulation of claim 1 , comprising about 0.1-5% (w/v) pH adjustment reagent.

7 . The formulation of claim 6 , comprising about 1-2% (w/v) pH adjustment reagent.

8 .- 9 . (canceled)

10 . The formulation of claim 1 , wherein the pH adjustment reagent is citric acid.

11 . The formulation of claim 10 , wherein the citric acid is anhydrous citric acid or citric acid monohydrate.

12 . The formulation of claim 1 , further comprising an isotonic reagent.

13 . The formulation of claim 12 , wherein the isotonic reagent is selected from sodium chloride and dextrose.

14 . The formulation of claim 1 , wherein the pH of the formulation is adjusted to about 4.0-8.0.

15 .- 16 . (canceled)

17 . The formulation of claim 1 , wherein the pH of the formulation is adjusted further with sodium hydroxide or hydrochloric acid or a combination thereof.

18 . The formulation of claim 1 , further comprising water.

19 . The formulation of claim 1 , comprising about 1.5-10% (w/v) compound of Formula (I), about 6-40% (w/v) solubilizer, and about 0.2-5% (w/v) pH adjustment reagent.

20 . The formulation of claim 1 , comprising about 10% (w/v) compound of Formula (I), about 40% (w/v) Hydroxypropyl Betadex, and about 1-2% (w/v) citric acid.

21 . The formulation of claim 1 , comprising about 1.00% (w/v) compound of Formula (I),
about 4.00% (w/v) Hydroxypropyl Betadex, about 0.168% (w/v) citric acid monohydrate, and water.

22 . A method of treating leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a formulation of claim 1 , wherein the formulation is administered continuously for at least 20 hours, at least 1 day, or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 21, 28, 35, 42, 47, 56, or 64 days.

23 .- 27 . (canceled)

28 . The method of claim 22 , wherein the subject is an adult and the formulation is administered at a dose of at least 90 mg/m 2 /day compound of Formula (I).

29 . The method of claim 22 , wherein the subject is a pediatric patient aged 12 months or younger and the formulation is administered at a dose of at least 45 mg/m 2 /day compound of Formula (I).

30 .- 35 . (canceled)

Assignees

• Epizyme Inc

Inventors

• Olhava Edward James
• Dovletoglou Angelos
• Wald Steve
• Rehlaender Bruce

Classifications

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title